Diabetes and Cardiovascular Disease by Francesco Paneni & Francesco Cosentino

Author:Francesco Paneni & Francesco Cosentino
Language: eng
Format: epub
Publisher: Springer International Publishing, Cham

ILLUMINATE (n = 15,067)

High CV risk

Torcetrapib plus atorvastatin vs. atorvastatin alone

Torcetrapib significantly increased median HDL-C while reducing LDL-C

Torcetrapib significantly increased the risk of CV events ([HR], 1.25; 95 % CI, 1.09–1.44; p = 0.001), and death from any cause ([HR],1.58; 95 % CI, 1.14–2.19; p = 0.006)

Dal-OUT-COMES (n = 15,871)

Recent ACS

Dalcetrapib or placebo, in addition to best available evidence-based care

Dalcetrapib significantly increased median HDL-C, with minimal effect on LDL-C

As compared with placebo, dalcetrapib did not alter the risk of the primary end point ([HR], 1.04; 95 % CI, 0.93–1.16; p = 0.52) and did not have a significant effect on any component of the primary end point or total mortality

Download

Copyright Disclaimer:
This site does not store any files on its server. We only index and link to content provided by other sites. Please contact the content providers to delete copyright contents if any and email us, we'll remove relevant links or contents immediately.